Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

The Hill and PhRMA Host Policy Discussion on Personalized Medicine

Precision Medicine 8Washington, DC, October 25, 2015 The Hill reports that in an era of personalization—where music apps filter songs based on listener preferences and online ads populated based on user search history — healthcare is the next frontier.

Scientific advances are transforming healthcare and ushering in a new era of personalized – or precision — medicine.  This approach makes it possible to account for each patient’s genetics, health history and lifestyle as researchers develop and doctors prescribe individualized treatments.

Such data-driven medicine has far-reaching policy implications, from regulations to delivery systems.

On October 22, The Hill hosted a discussion on the impact of this emerging field, the challenges to its progress, and how the Precision Medicine Initiative fits into the complex personalized medicine ecosystem.

The event was co-sponsored by the Pharmaceutical Research and Manufacturers of America (PhRMA).

To view the one-hour event, which was streamed live, on YouTube, click here.

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $51.2 billion in 2014 alone.